SOURCE: Brighton Markets

May 29, 2012 09:00 ET

Upcoming Economic Outlook - Report Highlights Genetic Technologies Limited (ADR) and Complete Genomics, Inc.

HONG KONG--(Marketwire - May 29, 2012) - Today, announced new reports highlighting Genetic Technologies Limited (ADR) (NASDAQ: GENE) and Complete Genomics, Inc. (NASDAQ: GNOM). Gain market insight with full analysis and research downloads available at

With markets in correction mode, investors are looking to quantify an accurate model, weighing positives and negatives of the months ahead. Upcoming negative pressures include China's slowdown, the European recession, the end of the Fed's Operation Twist stimulus program, continued geopolitical risks, election uncertainty, and potential 2013 budget bombshell of tax hikes and spending cuts. Meanwhile, positive offsets are driven by central banks (particularly China) cutting rather than hiking rates, deceleration in fuel and food prices, increase in consumer sentiment and resulting retail sales, signs of improvement in housing sales and new strength in auto production schedules.

Despite the current situation, our team continues to identify high momentum situations with growth potential -- there remains strong opportunity within careful discretion.

Brighton Markets is releasing new coverage on Genetic Technologies Limited (ADR) for its current position within the healthcare industry. Genetic Technologies Limited is engaged in a diagnostic product business. The Company translates genetic tests into products and services. The Company's cancer diagnostics business focused on building a sustainable stable of products and services. The Company operates in three divisions: genetic testing, including cancer diagnostics; licensing; and research. The full research report on Genetic Technologies Limited (ADR) (NASDAQ: GENE) is available here:

Brighton Markets has released research on Complete Genomics, Inc. for its changing role within the healthcare industry. Complete Genomics, Inc. is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. The full research report on Complete Genomics, Inc. (NASDAQ: GNOM) is available here:

About Brighton Markets
Brighton Markets was founded on the guiding principle of providing highly relevant, meaningful, and actionable information direct to investors. Across the investment spectrum, Brighton Markets shines light on today's events.

Contact Information